- 您現在的位置：買賣IC網 > PDF目錄358801 > LIPO (Electronic Theatre Controls, Inc.) Lipofectamine 2000 PDF資料下載
參數資料
| 型號： | LIPO |
| 廠商： | Electronic Theatre Controls, Inc. |
| 英文描述： | Lipofectamine 2000 |
| 中文描述： | 脂質體2000 |
| 文件頁數： | 1/2頁 |
| 文件大小： | 142K |
| 代理商： | LIPO |
Lipofectamine
2000
Cat. No. 11668-027
Cat. No. 11668-019
Contents and Storage
Lipofectamine
2000 is supplied in liquid form at a concentration of 1 mg/ml. Store at +4°C.
DO NOT FREEZE.
Product is
guaranteed for 6 months from the date of shipment if stored properly.
Size: 0.75 ml
Size: 1.5 ml
Description
Lipofectamine
2000 is a proprietary formulation suitable for the transfection of nucleic acids into eukaryotic cells. Using
Lipofectamine
2000 for transfection provides the following advantages:
96-well). Refer to the Transfection Collection and the
www.invitrogen.com for a list of cell lines and cell types that have been
with short interfering RNAs (siRNA) for use in RNA interference (RNAi) studies, see www.invitrogen.com\rnai
.
DNA-Lipofectamine
2000 complexes can be added directly to cells in culture medium (in the presence or absence of
serum).
It is not necessary to remove complexes or change or add medium following transfection, although complexes can be
removed after 4-6 hours without loss of activity.
Product Qualification
Lipofectamine
2000 is tested for the absence of microbial contamination using blood agar plates, Sabaraud dextrose agar plates,
and fluid thioglycolate medium, and functionally by transfection of CHO-K1 cells with a luciferase reporter-containing plasmid.
Important Guidelines
Follow these guidelines when performing transfections:
The ratio of DNA (in
μ
g):Lipofectamine
2000 (in
μ
l) to use when preparing complexes should be 1:2 to 1:3 for most cell
lines.
Some optimization may be necessary.
Example:
To transfect 0.5-2 x 10
5
cells in a 24-well format, use 0.8-1
μ
g DNA
and 2-3
μ
l of Lipofectamine
2000.
1.
2.
Transfect cells at high cell density
. 90-95% confluence at the time of transfection is recommended to obtain high efficiency
and expression levels, and to minimize decreased cell growth associated with high transfection activity. Lower cell densities
are suitable with optimization of conditions. Take care to maintain a standard seeding protocol between experi-ments
because transfection efficiency is sensitive to culture confluence.
3.
Do not add antibiotics
to media during transfection as this will cause cell death.
For optimal results, we also recommend the following:
Use Opti-MEM
I Reduced Serum Medium (Catalog no. 31985-062) to dilute Lipofectamine
2000 prior to complexing with
DNA. Other media without serum (
e.g.
D-MEM) may be used to dilute Lipofectamine
2000, but transfection efficiency may
be compromised.
Test serum-free media formulations for compatibility with Lipofectamine
2000 as some serum-free formulations can
inhibit cationic lipid-mediated transfection. CD 293, 293 SFM II, and VP-SFM are media formulations known to inhibit
transfection.
1.
2.
Limited Use Label License No. 27
The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer
(whether the buyer is an academic or for-profit entity). The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components
to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. The buyer may transfer information or
materials made through the use of this product to a scientific collaborator, provided that such transfer is not for any Commercial Purpose, and that such collaborator agrees in writing (a) to not
transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for research and not for Commercial Purposes. Commercial Purposes means any
activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a
service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such
product or its components are resold for use in research. Use of this product in conjunction with methods for the introduction of RNA molecules into cells may require licenses to one or more
patents or patent applications. Users of these products should determine if any licenses are required. Invitrogen Corporation will not assert a claim against the buyer of infringement of patents
owned by Invitrogen and claiming this product based upon the manufacture, use or sale of a therapeutic, clinical diagnostic, vaccine or prophylactic product developed in research by the buyer
in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. If the purchaser is not
willing to accept the limitations of this limited use statement, Invitrogen is willing to accept return of the product with a full refund. For information on purchasing a license to this product for
purposes other than research, contact Licensing Department, Invitrogen Corporation, 1600 Faraday Avenue, Carlsbad, California 92008. Phone (760) 603-7200. Fax (760) 602-6500.
25-0489B
Doc. Rev. 102202